Second Death Linked to Potential Antibody Treatment for Alzheimer’s Disease Woman’s brain hemorrhage while receiving Eisai’s widely heralded lecanemab heightens concerns overs its safety
By Charles Piller Global Research, November 30, 2022 Science 27 November 2022 A 65-year-old woman who was receiving a promising experimental treatment to slow the cognitive decline caused by her early Alzheimer’s disease recently died from a massive brain hemorrhage …Source
Second Death Linked to Potential Antibody Treatment for Alzheimer’s Disease

